Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
IRVINE, Calif., Sept. 21, 2017 -- MRI Interventions, Inc. (OTCQB:MRIC) (the “Company”), today announced that Frank Grillo, Chief Executive Officer, will present at the 2017 MicroCap Conference on Thursday, October 5, 2017, at 4:00 p.m. Eastern Time. The event will be held at The Essex House Hotel in New York, New York.
Management will be available to meet with investors throughout the day. Investors wishing to schedule a meeting may do so through the MicroCap Conference, http://microcapconf.com, or by contacting Matt Kreps, MRI Interventions’ Investor Relations, at [email protected].
About MRI Interventions, Inc.
Building on the imaging power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Forward-Looking Statements
Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Company’s cash resources. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, both of which have been filed with the Securities and Exchange Commission.
Contact Information:
Matt Kreps, Darrow Associates Investor Relations
Phone: (214) 597-8200
Email: [email protected]
